Mingxiang Liao
4 Papers
5 Citations
Mingxiang Liao is an academic researcher. The author has contributed to research in topics: Rucaparib & Cancer. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Evaluation of absorption, distribution, metabolism, and excretion of [ 14 C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
Mingxiang Liao,Simon Paul Watkins,Eileen Nash,Jeff Isaacson,Jeff Etter,Jeri Beltman,Rong Fan,Li Shen,Abdul Mutlib,Vendel Kemeny,Zsuzsanna Papai,Pascal van Tilburg,Jim J. Xiao +12 more
TL;DR: The data suggest that rucaparib is eliminated through multiple pathways, including metabolism and renal and biliary excretion, as well as the presence of metabolites in plasma.
A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Mingxiang Liao,Krzysztof G. Jeziorski,Monika Tomaszewska-Kiecana,István Láng,Marek Jasiówka,Viera Skarbova,Piotr Centkowski,Rodryg Ramlau,Maria Górnaś,John Y. Lee,Sarah Edwards,Jenn Habeck,Eileen Nash,Nikolay Grechko,Jim J. Xiao +14 more
TL;DR: In this article, the effect of rucaparib on the pharmacokinetics of rosuvastatin and oral contraceptives in patients with advanced solid tumors and their safety was evaluated.
Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor
TL;DR: The absorption, distribution, metabolism, elimination, and drug-drug interaction (DDI) potential of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib was characterised in vitro and DDI risk assessment using static models suggested potential CYP-related DDIs, with rucAParib as a perpetrator.
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
Nikolay Grechko,Viera Skarbova,Monika Tomaszewska-Kiecana,Rodryg Ramlau,Piotr Centkowski,Yvette Drew,Rafal Dziadziuszko,Milada Zemanova,Jeri Beltman,Eileen Nash,Jenn Habeck,Mingxiang Liao,Jim J. Xiao +12 more
TL;DR: In this paper, the authors investigated whether hepatic impairment affects the pharmacokinetics, safety, and tolerability of rucaparib in patients with advanced solid tumors, and the results suggest no starting dose adjustment is necessary for patients with moderate liver impairment; however, close safety monitoring is warranted.